2012-02-06 17:20:39 - Recently published research from Global Markets Direct, "Endometrial Cancer - Pipeline Review, H1 2012", is now available at Fast Market Research

Endometrial Cancer - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Endometrial Cancer - Pipeline Review, H1 2012', provides an overview of the Endometrial Cancer therapeutic pipeline. This report provides information on the therapeutic development for Endometrial Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometrial Cancer. 'Endometrial Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/330111_endometrial_cancer_pipeline_review_h1 ..


Note*: Certain

sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Endometrial Cancer.
* A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Endometrial Cancer pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Endometrial Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Endometrial Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Endometrial Cancer
Endometrial Cancer Therapeutics under Development by Companies
Endometrial Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Endometrial Cancer Therapeutics - Products under Development by Companies
Endometrial Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Endometrial Cancer Therapeutics Development
Bristol-Myers Squibb Company
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Genentech, Inc.
Merck & Co., Inc.
Novartis AG
Eisai Co., Ltd.
Pfizer Inc.
AEterna Zentaris Inc.
Critical Outcome Technologies Inc.
RXi Pharmaceuticals Corporation
Five Prime Therapeutics, Inc.
Endocyte, Inc.
Esperance Pharmaceuticals, Inc.
PharmaMar, S.A.
Endometrial Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEZS-108 - Drug Profile
E7080 - Drug Profile
RG7422 - Drug Profile
PF-05212384 - Drug Profile
Ridaforolimus - Drug Profile
SAR245408 - Drug Profile
FP-1039 - Drug Profile
Faslodex - Drug Profile
Dovitinib - Drug Profile
BEZ235 - Drug Profile
Zalypsis - Drug Profile
Trabectedin - Drug Profile
Bevacizumab + Temsirolimus - Drug Profile
Faslodex - Drug Profile
Aflibercept - Drug Profile
Trastuzumab - Drug Profile
Alvocidib - Drug Profile
EC145 - Drug Profile
Megestrol - Drug Profile
Avastin + Radiation Therapy - Drug Profile
Ixempra - Drug Profile
Fluorouracil + Doxorubicin - Drug Profile
Letrozole - Drug Profile
Carboplatin + Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Temsirolimus - Drug Profile
Ridaforolimus - Drug Profile
Alimta - Drug Profile
Paclitaxel + Carboplatin - Drug Profile
Ixabepilone - Drug Profile
Oxaliplatin - Drug Profile
Everolimus - Drug Profile
Cisplatin + Paclitaxel - Drug Profile
Carboplatin + Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile
Bevacizumab - Drug Profile
BKM120 - Drug Profile
Temsirolimus - Drug Profile
PF-04691502 - Drug Profile
Adriamycin + Cisplatin + Paclitaxel - Drug Profile
Adriamycin + Cisplatin - Drug Profile
Mifepristone - Drug Profile
Carboplatin + Paclitaxel + Avastin - Drug Profile
Docetaxel - Drug Profile
Paclitaxel + Carboplatin + Radiation Therapy - Drug Profile
Carboplatin + Docetaxel + Radiation Therapy - Drug Profile
Taxotere + Paraplatin - Drug Profile
MGI-114 - Drug Profile
Ethinyl Estradiol + Norgestrel - Drug Profile
Medroxyprogesterone - Drug Profile
Cetuximab - Drug Profile
Perifosine - Drug Profile
Perifosine - Drug Profile
Doxil - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330111&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.